In serious diseases, including cancer, it is common for there to be abnormalities in phosphorylation reactions, which are chemical reactions that occur between proteins. Accordingly, there are high expectations that clarifying phosphorylation reactions will lead to effective treatments. At present, however, because only a few phosphorylation reactions have been identified, there has been a problem in predicting large volumes of phosphorylation reactions caused by combinations of unknown proteins.
Now, by building a knowledge graph2 that can encompass an overview of the interrelations between proteins, it is possible to check the relationship between new proteins where phosphorylation reactions can be predicted. In this way, this technology will contribute to the advancement of medicine, as it can be expected to be useful on the front lines of drug discovery research, and have customized applications in the field of precision medicine3.
Speaking at the development announcement today Anthony McCauley, Head of Research at Fujitsu Ireland said “As Head of Research, I am very proud of this announcement today, as it demonstrates the enormous clinical benefit that can be realised by combining recent AI advances with biological expertise. Fujitsu has developed new predictive algorithms with the potential to accelerate the development or repurposing of drugs to target complex genetic disorders.
Our technique harnesses the power of knowledge graphs to capture, represent and interpret the ever increasing wealth of scientific data. From this graph representation, it predicts previously unknown relations between proteins of importance for biologist to better understand cancer and neurodegenerative diseases. Thus, it holds the promise of finding treatments quicker and reducing the cost of discovery of those treatments.
Fujitsu believes, this technology will contribute to the advancement of medicine, as it can be expected to be useful on the front lines of drug discovery research, and have customized applications in the field of precision medicine.”
Biological systems within the body are maintained by exchanges of information through the chemical reactions of various proteins within cells. In recent years, science has come to understand that many serious diseases, such as cancer, are partially caused by abnormalities in phosphorylation reactions, which are representative of the chemical reactions between proteins. If pharmaceuticals that repaired abnormal phosphorylation reactions could be developed, that would enable more effective treatments. At present, however, only a few phosphorylation reactions are well understood, so there is a need for the discovery of unknown phosphorylation reactions, and to enrich the data on phosphorylation reactions.
When this technology was tested using evaluation data4, the model was trained on phosphorylation reactions (9,802 reactions), and predicted 11,581,940 new phosphorylation reactions. This showed its capability in predicting about twice as many phosphorylation reactions compared to conventional technology that trained AI on the structure of amino acid sequences, without significant change to prediction accuracy.
In addition, in order to test whether phosphorylation reactions predicted using this technology could actually occur within a living being, tests were conducted by Systems Biology Ireland5, an Irish biological research institution and a joint research partner, using mass spectrometry equipment and antibodies In this test, experts in biology selected and tested a few phosphorylation reaction prediction results for proteins related to cancer, and were able to confirm nine phosphorylation reactions, of which eight were reactions that could not have been predicted with conventional technology.
Systems Biology Ireland (SBI) director Walter Kolch, a world leading authority on systems biology research, said about these results ”Combining Fujitsu’s knowledge graph technology with SBI’s understanding of biological networks, we have developed a new computational method that can predict which kinase phosphorylates which substrates. The method is accurate and could discover previously unknown phosphorylation sites, a major step forward for new drug development and more focused precision medicine.”
By combining data on new phosphorylation reactions predicted by this technology with other biomedical data, it is expected to connect the chemical reactions from the causes of a disease (abnormalities in phosphorylation reactions) to the disease’s symptoms, which can then be provided to those on the front lines of research as useful information in drug discovery. The effectiveness of treatments for diseases such as cancer can vary widely between patients. This technology, however, is expected to clarify the individual variation in the effects of treatments, contributing to the promotion of medicine tailored to individual patients.
Fujitsu Laboratories and the Insight Centre will continue to further improve the accuracy of this technology to process biomedical data with knowledge graphs, extending the technology to biomedical projects at Fujitsu Limited in fiscal 2018. Moreover, by incorporating this technology into Fujitsu’s AI technology, including Fujitsu Human Centric AI Zinrai, the organizations plan to accelerate the biomedical business.
Glossary and Notes
1The Insight Centre for Data Analytics: A data analytics research institution, one of the largest in Europe, run by Science Foundation Ireland. The Insight Centre has several locations in Ireland, but this announcement is in regard to a joint research conducted with its location at the National University of Ireland Galway.
2Knowledge graph: A dataset that uses connections representing relationships between information collected from a variety of information sources.
3Precision medicine: A new style of medicine that prevents and treats diseases with consideration of individual differences in genetic information, living environment, and lifestyle.
4Evaluation data: PhosphoSitePlus, a database of phosphorylation reactions, and UniProt, a database of protein sequences.
5Systems Biology Ireland: A systems biology research institution specialized in the study of cellular information transmission, with a focus on developing new treatment strategies for cancer
“Ground-breaking Multi-disciplinary Project Could Lead to New Targeted Therapies for Cancer,” (press release, March 8, 2017):
Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 140,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.1 trillion yen (US $39 billion) for the fiscal year ended March 31, 2018. For more information, please see: http://www.fujitsu.com.
A data analytics research institution, one of the largest in Europe, run by Science Foundation Ireland. The Insight Centre has several locations in Ireland, but this announcement is in regard to a joint research conducted with its location at the National University of Ireland Galway. For more information, please see: https://www.insight-centre.org/
Founded in 1968 as a wholly owned subsidiary of Fujitsu Limited, Fujitsu Laboratories Ltd. is one of the premier research centers in the world. With a global network of laboratories in Japan, China, the United States and Europe, the organization conducts a wide range of basic and applied research in the areas of Next-generation Services, Computer Servers, Networks, Electronic Devices and Advanced Materials. For more information, please see: http://www.fujitsu.com/jp/group/labs/en/
Mobile: Ph: 01 907 9987 / 01 907 9962
Phone: 086 840 4761
Company:FH Media Consulting (The Insight Centre for Data Analytics)
Date: 31 October, 2018
Share this page